CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
| Autor: | Fariborz Mortazavi, Warren D. W. Heston, James P. Allison, Polly D. Gregor, Alan N. Houghton, Miguel-Angel Perales, Michel Sadelain, Dean J. Bacich, Heidi Buchinshky, Jean Baptiste Latouche, Howard I. Scher, José A. Guevara-Patiño, Jedd D. Wolchok, Cristina R. Ferrone |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Cellular immunity Antibodies Neoplasm T-Lymphocytes T cell Melanoma Experimental Autoimmunity chemical and pharmacologic phenomena Biology Autoantigens Cancer Vaccines DNA vaccination Mice Antigen Antigens CD Immunity Cell Line Tumor Neoplasms Vaccines DNA medicine Animals Humans CTLA-4 Antigen Immunization Schedule Immunity Cellular Mice Inbred BALB C General Veterinary General Immunology and Microbiology Prostate Public Health Environmental and Occupational Health hemic and immune systems Flow Cytometry Antigens Differentiation Blockade Mice Inbred C57BL Vaccination Infectious Diseases medicine.anatomical_structure CTLA-4 Immunology Molecular Medicine Immunosuppressive Agents Neoplasm Transplantation Plasmids |
| Zdroj: | Vaccine. 22:1700-1708 |
| ISSN: | 0264-410X |
| Popis: | Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-4 blockade could increase T-cell responses and tumor immunity elicited by DNA vaccines. CTLA-4 blockade enhanced B16 tumor rejection in mice immunized against the melanoma differentiation antigens tyrosinase-related protein 2 and gp100, and this effect was stronger when anti-CTLA-4 was administered with booster vaccinations. CTLA-4 blockade also increased the T-cell responses to prostate-specific membrane antigen (PSMA) when given with the second or third vaccination. Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect